NeuroOne Celebrates First Implant of OneRF™ Ablation Electrode at Top-Ranked Hospital

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced that doctors at a top-ranked US hospital have successfully performed the first implant of the company’s OneRF™ Ablation Evo® sEEG-RF electrode. NeuroOne’s OneRF™ Ablation system is a thin film stereoelectroencephalography (sEEG)-guided radiofrequency (RF) system and is designed for recording electrical activity and ablating nervous tissue using a single electrode.

Commenting on the milestone, NeuroOne CEO, Dave Rosa, said, “We are excited to announce that yesterday, doctors implanted Evo® sEEG-RF electrodes in a patient suffering from epilepsy. Once the monitoring identifies the areas of the brain that are causing seizures, the surgical team now has the option to use the same electrodes to perform an ablation utilizing NeuroOne’s RF generator. This capability provides the neurosurgeon an entirely new option for use in the appropriate patients and situation.”

Being first to market with this technology positions NeuroOne as a market leader in offering multi-functional diagnostic and therapeutic thin-film electrode technology. The company believes that its technology has the potential to reduce hospital stays, number of surgeries, and adverse events, while offering significant clinical benefits – including temperature controlled ablation – to enhance patient safety.

Last month, NeuroOne initiated a limited commercial launch of its OneRF™ Ablation system, shipping systems to participating centers in March and beginning patient treatments in April.


The OneRF™ Ablation system has FDA 510(k) clearance for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

NeuroOne has developed a full line of thin film electrode technology for diagnostic brain mapping procedures and RF ablation.

The company’s other FDA-cleared devices include the Evo® cortical and sEEG electrode product lines which are used for stimulation, recording and monitoring of electrical activity in the brain.

NeuroOne estimates the rapidly growing current brain ablation market to be valued at approximately $100 million worldwide.

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence solutions. For more information, visit


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

NeuroOne Celebrates First Implant of OneRF™ Ablation Electrode at Top-Ranked Hospital

Catie Corcoran

Biotech Editor